3 Houston innovators to know this week

who's who

This week's Houston innovators to know includes Sola Lawal of Nuro, Jose Diaz-Gomez of CHI St. Luke's Health, and Kimberly Baker of UT School of Public Health. Courtesy photos

Editor's note: A key attribute of innovators and inventors is the ability to look forward — to see the need for their innovation and the difference it will make. Each of this week's innovators to know have that skill, whether it's predicting the rise of autonomous vehicles or seeing the future of health care.

Sola Lawal, product operations manager at Nuro

Autonomous vehicle delivery service is driving access to food in Houston’s vulnerable communities

Native Houstonian Sola Lawal is looking into how AI and robotics can help increase access to fresh foods in local food deserts. Photo courtesy of Nuro

Sola Lawal has always found himself back in his hometown of Houston. Now working for artificial intelligence and robotics company, Nuro, he sees the potential Houston has to become a major market for autonomous vehicles.

"I think that autonomous vehicles are going to become an industry in the same way your standard vehicles are," Lawal says."One really strong way the Houston ecosystem and Nuro can partner is essentially building out the ancillary."

Lawal shared more on how Houston and Nuro can work together on this week's episode of the Houston innovators podcast. Read more and stream the episode.

Jose Diaz-Gomez, an anesthesiologist at CHI St. Luke's Health

CHI St. Luke's Health has invested in around 40 of the Butterfly iQ devices that can be used to provide accurate and portable ultrasonography on COVID-19 patients. Photo courtesy of CHI St. Luke's

A new, portable ultrasound device has equipped Jose Diaz-Gomez and his team with a reliable, easy-to-use tool for diagnostics and tracking progress of COVID-19 patients. And this tool will continue to help Diaz-Gomez lead his team of physicians.

"Whatever we will face after the pandemic, many physicians will be able to predict more objectively when a patient is deteriorating from acute respiratory failure," he says. "Without this innovation, we wouldn't have been able to be at higher standards with ultrasonography." Read more.

Kimberly A. Baker, assistant professor at UTHealth School of Public Health

UTHealth School of Public Health launched its Own Every Piece campaign to promote women's health access and education. Photo courtesy of Own Every Piece

It was unnerving to Kimberly Baker that proper sex education wasn't in the curriculum of Texas schools, and women were left without resources for contraceptives. So, along with UTHealth School of Public Health, she launched its Own Every Piece campaign as a way to empower women with information on birth control and ensure access to contraceptive care regardless of age, race, relationship status or socioeconomic status.

"You feel like the campaign is talking to you as a friend, not talking down to you as an authority or in any type of shaming way," says Kimberly A. Baker, assistant professor at UTHealth School of Public Health. One of her favorite areas of the website is the "Find a Clinic" page, connecting teens and adult women to nearby clinics, because "one of the biggest complaints from women is that they didn't know where to go," says Baker. Continue reading.

CHI St. Luke's Health has invested in around 40 of the Butterfly iQ devices that can be used to provide accurate and portable ultrasonography on COVID-19 patients. Photo courtesy of CHI St. Luke's

Houston hospital taps new tech to provide more accurate COVID-19 diagnostics and treatment

hand held

With such a dynamic virus like COVID-19 that affects patients with different levels of severity, the first challenge doctors face when treating infected patients is assessing the situation. CHI St. Luke's Health has been implementing a new technology that allows its physicians better access to that initial diagnosis.

Dr. Jose Diaz-Gomez, an anesthesiologist at CHI St. Luke's Health and ultrasonography expert, says the Butterfly iQ's portable ultrasonography technology has been a key tool in his team's point of care for COVID-19 patients. Over the past few years, ultrasonography equipment has been evolving to be more portable and more accurate. That's what the Butterfly iQ technology provides, and Diaz-Gomez says his team was quick to realize how the technology can help in diagnostics and treatment of coronavirus patients.

A traditional approach to examining a patient's lungs would mean radiography, but Diaz-Gomez says his team saw the opportunity ultrasonography and these new, portable devices had on providing more accurate and timely diagnostics.

"In conditions that are dynamic, you want to have a diagnostic tool that, over time as you're treating a patient, you can see meaningful changes — good or bad," Diaz-Gomez says. "The pandemic has enabled us to use — from the initial care to when they are on the ventilator — ultrasonography to see the changes in the patient's' lungs."

Jose Diaz-Gomez is an anesthesiologist at CHI St. Luke's. Photo courtesy of CHI St. Luke's

The Butterfly iQ device is different from its ultrasound predecessors in that it's built to be more accurate, portable, easy to use, and low cost (even being made available for commercial purchase). According to Diaz-Gomez, he could train someone on the device in just a few hours.

Ahead of the pandemic, CHI St. Luke's had 20 of these devices and now has doubled that initial fleet. Along with the other non-Butterfly iQ ultrasonography devices, Diaz-Gomez's team has access to 70 ultrasonography devices — 80 percent of which are dedicated to COVID-19 patients.

"Our institution was very supportive of bringing a very robust roll-out program for point-of-care ultrasonography during the pandemic," Diaz-Gomez says. "We were able to incorporate 40 ultrasound devices — the Butterfly system. Not only that, we actually implemented a very rigorous infection control process to make sure we do it in a safe manner. You don't want to bring tools that will be another source of transmission from patient to patient."

While this new technology is continuing to make a difference in St. Luke's COVID units, Diaz-Gomez is already looking forward to the difference the devices will make post pandemic.

"Whatever we will face after the pandemic, many physicians will be able to predict more objectively when a patient is deteriorating from acute respiratory failure," he says. "Without this innovation, we wouldn't have been able to be at higher standards with ultrasonography."

The device, with its portability, low cost, and ease of use, also has an application for telemedicine and at-home health, and that's something that's exciting for Diaz-Gomez. However, both in his COVID units or in the home setting, the device is only as good as the clinician who's interpreting the images paired with the other diagnostics.

"The integration of ultrasonography with the clinical practice itself — it has to go hand in hand," Diaz-Gomez says. "The clinical decision will depend on that integration."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston geothermal unicorn Fervo officially files for IPO

going public

Fervo Energy has officially filed for IPO.

The Houston-based geothermal unicorn filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission on April 17 to list its Class A common stock on the Nasdaq exchange. Fervo intends to be listed under the ticker symbol "FRVO."

The number and price of the shares have not yet been determined, according to a news release from Fervo. J.P. Morgan, BofA Securities, RBC Capital Markets and Barclays are leading the offering.

The highly anticipated filing comes as Fervo readies its flagship Cape Station geothermal project to deliver its first power later this year

"Today, miles-long lines for gasoline have been replaced by lines for electricity. Tech companies compete for megawatts to claim AI market share. Manufacturers jockey for power to strengthen American industry. Utilities demand clean, firm electricity to stabilize the grid," Fervo CEO Tim Latimer shared in the filing. "Fervo is prepared to serve all of these customers. Not with complex, idiosyncratic projects but with a simplified, standardized product capable of delivering around-the-clock, carbon-free power using proven oil and gas technology."

Fervo has been preparing to file for IPO for months. Axios Pro first reported that the company "quietly" filed for an IPO in January and estimated it would be valued between $2 billion and $3 billion.

Fervo also closed $421 million in non-recourse debt financing for the first phase of Cape Station last month and raised a $462 million Series E in December. The company also announced the addition of four heavyweights to its board of directors last week, including Meg Whitman, former CEO of eBay, Hewlett-Packard, and Spring-based HPE.

Fervo reported a net loss of $70.5 million for the 2025 fiscal year in the S-1 filing and a loss of $41.1 million in 2024.

Tracxn.com estimates that Fervo has raised $1.12 billion over 12 funding rounds. The company was founded in 2017 by Latimer and CTO Jack Norbeck.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

New UT Austin med center, anchored by MD Anderson, gets $1 billion gift

Future of Health

A donation announced Tuesday, April 21, breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release.

The release also records "significant support" for undergraduate scholarships, student housing, and the Texas Advanced Computing Center for supercomputing research.

Both the new research campus and the UT Dell Medical Center will integrate advanced computing into their research and practices. At the medical center, the university hopes that will lead to "earlier detection, more precise and personalized care, and better health outcomes." The University of Texas MD Anderson Cancer Center will also be integrated into the new medical center.

That comes with a numeric goal measured in 10s: raise $10 billion and rank among the top 10 medical centers in the U.S., both in the next decade.

In the shorter term, the university will break ground on the medical center with architecture firm Skidmore, Owings & Merrill (SOM) "later this year."

“UT Austin, where Dell Technologies was founded from a dorm room, has always been a place where bold ideas become real-world impact,” said Michael and Susan Dell in a joint statement.

They continued, “What makes this moment so meaningful is the opportunity to build something that brings every part of the journey together — from how students learn, to how discoveries are made, to how care reaches families. By bringing together medicine, science and computing in one campus designed for the AI era, UT can create more opportunity, deliver better outcomes, and build a stronger future for communities across Texas and beyond.”

This is the second major gift this year for the planned multibillion-dollar medical center. In January, Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed $100 million$100 million.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

Alzheimer’s research

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March.

Dr. Ryan S. Dhindsa is an assistant professor of pathology & immunology at Baylor and a principal investigator at Texas Children’s Duncan Neurological Research Institute (Duncan NRI). He hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation.

“It is an honor to receive this support from the Cure One, Cure Many Award. Viral infections are emerging as a major, underappreciated driver of Alzheimer's disease, and this award will allow our team to conduct the most comprehensive screen of viral exposures and host genetics in Alzheimer's to date, spanning over a million individuals,” Dhindsa said in a news release. “Our goal is to identify which viruses matter most, why some people are more vulnerable than others, and ultimately move the field closer to new therapeutic strategies for patients.”

Roughly 150 million people worldwide will suffer from Alzheimer’s by 2050, making it the most common cause of dementia in the world. Despite this, scientists are still at a loss as to what exactly causes it.

Dhindsa’s research is part of a new range of theories that certain viral infections may trigger Alzheimer’s. His team will take a two-fold approach. First, they will analyze the medical records of more than a million individuals looking for patterns. Second, they will analyze viral DNA in stem cell-derived brain cells to see how the infections could contribute to neurological decay. The scale of the genomic data gathering is unprecedented and may highlight a link that traditional studies have missed.

Also joining the project are Dr. Caleb Lareau of Memorial Sloan Kettering Cancer Center and Dr. Artem Babaian of the University of Toronto. Should a link be found, it would open the door to using anti-virals to prevent or treat Alzheimer’s.

View All Listings